1. Home
  2. FOXX vs RNXT Comparison

FOXX vs RNXT Comparison

Compare FOXX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FOXX

Foxx Development Holdings Inc.

HOLD

Current Price

$4.62

Market Cap

35.6M

Sector

N/A

ML Signal

HOLD

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

HOLD

Current Price

$0.86

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
RNXT
Founded
2017
2012
Country
United States
United States
Employees
25
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
37.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FOXX
RNXT
Price
$4.62
$0.86
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.25
AVG Volume (30 Days)
4.4M
318.2K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.00
EPS
N/A
N/A
Revenue
N/A
$1,123,000.00
Revenue This Year
N/A
$194.66
Revenue Next Year
N/A
$279.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2511.63
52 Week Low
$1.71
$0.70
52 Week High
$8.70
$1.45

Technical Indicators

Market Signals
Indicator
FOXX
RNXT
Relative Strength Index (RSI) 54.26 46.08
Support Level $4.03 $0.79
Resistance Level $5.15 $1.07
Average True Range (ATR) 0.89 0.07
MACD 0.24 0.00
Stochastic Oscillator 41.62 37.82

Price Performance

Historical Comparison
FOXX
RNXT

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: